
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. When Centers for Medicare and Medicaid (CMS) coverage rules are not fully developed, this medical policy may be used by BCBSM or BCN Medicare Advantage plans 42 CFR § 422.101 (b)(6).

Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 7/1/26**
(See policy history boxes for previous effective dates)

Title: Myocardial Sympathetic Innervation Imaging – Heart Failure

Description

Myocardial sympathetic innervation imaging is a nuclear-medicine technique used to assess the distribution and function of sympathetic nerve terminals in the heart muscle. It provides unique information about cardiac autonomic regulation that cannot be obtained from standard anatomical or perfusion imaging. Iodine 123 meta-iodobenzylguanidine (MIBG) is the typical tracer used during the imaging.

Medical Policy Statement

Myocardial sympathetic innervation imaging with ¹²³I meta-iodobenzylguanidine and single-photon emission computed tomography (SPECT) is experimental/ investigational. There is insufficient evidence to determine that the technology results in an improvement in net health outcomes.

Inclusionary and Exclusionary Guidelines

N/A

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

N/A

Other codes (investigational, not medically necessary, etc.):

0331T

0332T

A9582

Background

In individuals with heart failure, activation of the sympathetic nervous system is an early response to compensate for decreased myocardial function. The concentration of iodine 123 meta-iodobenzylguanidine (MIBG) over several hours after injection of the agent is a potential marker of sympathetic neuronal activity. MIBG activity is proposed as a prognostic marker in patients with heart failure to aid in the identification of individuals at risk of 1- and 2-year mortality. The marker could also be used to guide treatment decisions or to monitor the effectiveness of heart failure treatments.

Heart Failure

An estimated 6.7 million adults in the United States have heart failure. In 2022, heart failure was mentioned on 457, 212 death certificates in the U.S.(1) According to data in the 2022 Heart and Stroke Statistics Update, 1 in 6 patients with heart failure and reduced ejection fraction developed worsening disease within 18 months of diagnosis and these individuals were more likely to be Black, >80 years of age, and have increased comorbidity burden.(2) Black individuals also have the highest risk of developing heart failure in the future, followed by Hispanic, White, and Chinese American individuals, reflecting disparities in the incidence of hypertension, diabetes, and socioeconomic status among these populations. Black individuals also have the highest proportion of incident heart failure not preceded by myocardial infarction (75%). Underlying causes of heart failure include coronary artery disease, hypertension, valvular disorders, and primary cardiomyopathies. These conditions reduce myocardial pump function and decrease left ventricular ejection fraction. An early mechanism to compensate for this decreased myocardial function is activation of the sympathetic nervous system. The increased sympathetic activity initially helps compensate for heart failure by increasing heart rate and myocardial contractility to maintain blood pressure and organ perfusion. However, over time, this places additional strain on the myocardium, increasing coronary perfusion requirements, which can lead to worsening of ischemic heart disease and or myocardial damage. As the ability of the heart to compensate for reduced myocardial function diminishes, clinical symptoms of heart failure develop. Another detrimental effect of heightened sympathetic activity is an increased susceptibility to potentially fatal ventricular arrhythmias.

Overactive sympathetic innervation associated with heart failure involves increased neuronal release of norepinephrine (NE), the main neurotransmitter of the cardiac sympathetic nervous system. In response to sympathetic stimulation, vesicles containing NE are released into the neuronal synaptic cleft. The released NE binds to postsynaptic beta-1, beta-2 and alpha

receptors, enhances adenyl cyclase activity and brings about the desired cardiac stimulatory effects. NE is then taken back into the presynaptic space for storage or catabolic disposal terminating the synaptic response by the uptake-1 pathway. The increased release of NE is usually accompanied by decreased NE reuptake, thereby further increasing circulating NE levels.

Diagnostic Imaging

Guanethidine is a false neurotransmitter that is an analog of NE; it is also taken up by the uptake-1 pathway. Iodine 123 meta-iodobenzylguanidine (¹²³I-MIBG or MIBG) is chemically modified guanethidine labeled with radioactive iodine. MIBG moves into the synaptic cleft and then is taken up and stored in the presynaptic nerve space in a manner that is similar to NE. However, unlike NE, MIBG is not catabolized and thus concentrates in myocardial sympathetic nerve endings. This concentrated MIBG can be imaged with a conventional gamma camera.(3) The concentration of MIBG over several hours after injection is thus a reflection of sympathetic neuronal activity, which in turn may correlate with the severity of heart failure.

Iodine 123 meta-iodobenzylguanidine myocardial imaging has been in use in Europe and Japan and standardized procedures for imaging have been proposed by European organizations.(4) Administration of MIBG is recommended by slow (1-2 minutes) injection. Planar images of the thorax are acquired 15 minutes (early image) and 4 hours (late image) after injection. In addition, optional single-photon emission computed tomography (SPECT) imaging can be performed following the early and late planar images. MIBG uptake is semi-quantified by determining the average count per pixel in regions of interest drawn over the heart and the upper mediastinum in the planar anterior view. There is no single universally used myocardial MIBG index. The most commonly used myocardial MIBG indices are the early heart to mediastinum (H/M) ratio, late H/M ratio, and the myocardial MIBG washout rate. The H/M ratio is calculated by taking the average count per pixel in the myocardium divided by the average count per pixel in the mediastinum. The myocardial washout rate is expressed as the rate of decrease in myocardial counts over time between early and late imaging (normalized to mediastinal activity).

Iodine 123 meta-iodobenzylguanidine activity is proposed as a prognostic marker in patients with heart failure, to be used in conjunction with established markers or prognostic models to identify heart failure patients at increased risk of short-term mortality. MIBG activity could also potentially be used to guide treatment decisions or to monitor the effectiveness of heart failure treatments.

Summary of Evidence

For individuals with heart failure who receive imaging with MIBG for prognosis, the evidence includes numerous studies that MIBG cardiac imaging findings predict outcomes in individuals with heart failure. The relevant outcomes are overall survival, disease-specific survival, functional outcomes, health status measures, quality of life, hospitalizations, and medication use. While the available studies vary in their patient inclusion criteria and methods for analyzing MIBG parameters, the highest quality studies demonstrate a significant association between MIBG imaging results and adverse cardiac events, including cardiac death. Moreover, MIBG findings have been shown to improve the ability of the Seattle Heart Failure Model and other risk models to predict mortality. However, there is no direct published evidence on the

clinical utility of MIBG (i.e., whether findings of the test would lead to patient management changes that improve health outcomes) and no chain of evidence can be constructed to support clinical utility. Management changes made as a result of MIBG imaging are uncertain, and it is not possible to determine whether management changes based on MIBG results lead to improved health outcomes compared with management without MIBG imaging. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to individuals and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms. The following is a summary of the key literature to date.

The U.S. Food and Drug Administration (FDA)–approved indication for the scintigraphic imaging agent meta-iodobenzylguanidine (MIBG) in individuals with heart failure is to measure the heart to mediastinum (H/M) ratio, which can be used to predict risk of 1- and 2-year mortality. While the H/M ratio can be used as either a dichotomous or continuous variable, the FDA-approved indication is a dichotomous variable with an in H/M cutoff of 1.6. A ratio less than 1.6 indicates higher risk, and a ratio of 1.6 or greater indicates a lower risk.⁽⁷⁾ Thus, evaluation of this technology involves first searching for evidence that an H/M ratio of at least 1.6 is statistically associated with mortality in individuals with heart failure.

MYOCARDIAL SYMPATHETIC INNERVATION IMAGING IN HEART FAILURE

Clinical Context and Test Purpose

The purpose of prognostic imaging using MIBG in individuals with heart failure is to risk stratify them to determine the appropriate next steps.

Review of Evidence

The first step in evaluating MIBG is evaluating its prognostic accuracy, specifically, whether an H/M ratio of less than 1.6 is associated with a higher risk of heart failure mortality.

Systematic Reviews

Verschure et al (2014) published the results of an individual patient data meta-analysis to assess which heart failure–related end point had the strongest association with MIBG results.⁽⁸⁾ The meta-analysis included 636 patients with congestive heart failure from six studies from the United States and Europe. Inclusion criteria were studies reporting survival in patients with heart failure stratified by the H/M ratio, which yielded eight studies, six of which were willing to share individual patient data. Over a mean follow-up of 36.9 months, 159 patients had 172 events: 83 deaths (67 of which were cardiac), 33 arrhythmic events, and 56 cardiac transplantations. In univariate analysis, the H/M ratio was significantly associated with all cardiac-related outcomes, but the lowest hazard ratios (HR) were associated with the

composite end point of any event (HR=0.30; 95% CI, 0.19 to 0.46), all-cause mortality (HR=0.29; 95% confidence interval [CI], 0.16 to 0.53), and cardiac mortality (HR=0.28; 95% CI, 0.14 to 0.55).

A systematic review by Verberne et al (2008) selected studies that reported survival in patients with heart failure stratified by MIBG myocardial parameters (early H/M, late H/M, and/or myocardial washout).(9) Eighteen studies met the eligibility criteria. Thirteen studies were prospective, and all but one had at least 3 months of follow-up. Sample sizes ranged from 37 to 205 patients; 5 studies included more than 100 patients. Patient populations varied across studies. Some studies included the whole heart failure spectrum (i.e., New York Heart Association [NYHA] functional status class 1 to IV) and others focused on a narrower range of functional status. Fourteen studies included patients with depressed left ventricular ejection fraction (LVEF; <40%). Acquisition of early H/M was performed at 15 to 20 minutes in 9 studies and ranged from 30 to 60 minutes in the other 6 studies. Seventeen studies acquired late H/M at 240 minutes after injection. Reviewers evaluated methodologic quality using a tool they developed to rate each study; the scoring range was 0 to 9. The median quality score of the included studies was six; two studies scored 9.

In reviewers' initial calculations, the pooled hazard ratio (HR) for death and late H/M ratio and for a cardiac event and late H/M showed significant heterogeneity among studies, and therefore pooled results were not presented for the entire body of studies. Reviewers eliminated statistical heterogeneity by selecting the highest quality studies (i.e., top fifth in terms of quality score, n=3 studies). When findings from these 3 highest quality studies were pooled, there was a statistically significant effect of MIBG on cardiac events (HR=1.98; 95% confidence interval [CI], 1.57 to 2.50). However, when findings from the 2 highest quality studies reporting the outcome of cardiac death were pooled, there was not a statistically significant effect of MIBG on this outcome (HR=1.82; 95% CI, 0.80 to 4.12). The reviewers did not pool findings on the prognostic value of early H/M or myocardial washout due to failure to identify a subset of studies without heterogeneity.

Prospective Studies

ADMIRE-HF Study

Jacobson et al (2010) published data from two prospective, multicenter industry-sponsored studies, together known as the AdreView Myocardial Imaging for Risk Evaluation in Heart Failure (ADMIRE-HF) study.(10) This study was the primary evidence used by the Food and Drug Administration (FDA) to grant approval for AdreView. The analysis presented the combined primary efficacy results of the two studies. The study included patients with NYHA functional class II or III heart failure and LVEF of 35% or lower, which are the clinical parameters specified by the FDA documents as the appropriate criteria for use of AdreView in heart failure patients. In addition, patients had to be treated with optimum pharmacotherapy. Major exclusion criteria were serum creatinine above 3.0 mg/dL, functioning ventricular pacemaker and cardiac revascularization, myocardial infarction, or implantable cardioverter defibrillator implantation within the past 30 days

Patients received an injection of MIBG then underwent planar and single-photon emission computerized tomography (SPECT) imaging of the thorax at 15 minutes after injection (early) and at 3 hours and 50 minutes after injection (late). The H/M ratio, on a scale from 0 to 4, was determined from both the early and late images. Patients then received standard clinical care

and were followed for 2 years. The primary analysis evaluated the association between time to first cardiac event occurrence and the late H/M ratio categorized as under 1.6 or 1.6 and higher. The authors also evaluated the association between time to first cardiac event occurrence and late H/M ratio as a continuous variable. The composite outcome of cardiac events was defined as the occurrence of either 1) heart failure progression (i.e., increase of ≥ 1 NYHA functional class); 2) potentially life-threatening arrhythmic event (i.e., spontaneous ventricular tachyarrhythmia for >30 seconds, resuscitated cardiac arrest, or appropriate discharge of implantable cardiac defibrillator); or 3) cardiac death.

A total of 985 patients underwent MIBG imaging (435 in the first study, 532 in the second study) and 961 (98%) patients were available for analysis. There were 760 (79%) patients with an H/M less than 1.60 and 201 patients (21%) with H/M at least 1.60. Patients were followed for a median of 17 months (range, 2 days-30 months). Cardiac events occurred in 237 (25%) of 961 patients. The mean late H/M ratio (SD) was 1.39 (0.18) in the group of patients with events and 1.46 (0.21) in the group of patients without events. The risk of cardiac events was significantly lower for patients with an H/M at least 1.6 compared with those with an H/M less than 1.6 (HR=0.40; 97.5% CI, 0.25 to 0.64; $p<0.001$). In addition, there was a statistically significant association between the cardiac event rate and H/M ratio as a continuous variable, with lower event rates on patients with higher H/M ratios (HR=0.22; 95% CI, 0.10 to 0.47; $p<0.001$). The estimate of 2-year all-cause mortality was 16.1% for patients with an H/M less than 1.60 and 3.0% for patients with an H/M at least 1.60 ($p<0.001$). The authors also compared H/M ratio with other prognostic markers. In a multivariate model including the H/M ratio, b-type natriuretic peptide, LVEF, and NYHA functional class, all four markers were independently associated with time to cardiac events.

Ketchum et al (2012) published an analysis incorporating MIBG imaging findings into the Seattle Heart Failure Model (SHFM) using survival data from the 961 patients included in the primary efficacy analysis of the ADMIRE-HF study.(11) The late H/M ratio from MIBG imaging was divided into 5 categories: less than 1.2, 1.2 to 1.39, 1.40 to 1.59, 1.6 to 1.79, and at least 1.8. (Note that this differs from the dichotomous late H/M variable, <1.60 and at least 1.60, used in the main ADMIRE-HF analysis). In a Cox proportional hazards model, SHFM and H/M were both independent predictors of overall survival. There was an 82.1% increase in risk for 1 SD change in the SHFM ($p<0.001$) and a 60.3% increase in risk for 1 standard deviation (SD) change in the late H/M ratio ($p<0.001$). For the outcome of cardiac mortality, each SD increase in SHFM was associated with an 86.1% increase in risk ($p<0.001$), and each SD increase in the late H/M ratio was associated with a 57.9% increase in risk ($p=0.002$). In an area under the curve (AUC) analysis, the addition of H/M to the SHFM significantly improved the prediction of all-cause mortality compared with the SHFM alone. When H/M was added to the SHFM, the AUC increased by 0.039 ($p=0.026$) for 1-year mortality and the AUC increased by 0.028 ($p<0.05$) for 2-year mortality.

Al Badarin et al (2014) conducted another subgroup analysis of the ADMIRE-HF study to evaluate whether the addition of MIBG scintigraphy to conventional markers of arrhythmic risk had an incremental predictive value for arrhythmic events in patients with heart failure.(12) This analysis included 778 patients, from ADMIRE-HF with LVEF less than 35% and NYHA class II or III heart failure symptoms, who did not have an implantable cardioverter-defibrillator (ICD) at the time of enrollment. Of these, 6.9% experienced the primary end point of an arrhythmic event, which was a composite of sudden cardiac death, appropriate ICD therapy, resuscitated cardiac arrest, or sustained ventricular tachycardia. An H/M ratio less than 1.6

was significantly associated with risk of arrhythmic events (HR=3.48; 95% CI, 1.52 to 8; p=0.02). Other predictors of arrhythmic events were LVEF less than 25% and systolic blood pressure (SBP) less than 120. The authors derived a risk score, incorporating the H/M ratio, SBP, and LVEF. Risk scores ranged from -3 to 20, with higher scores associated with an increased risk of arrhythmic events. Stratified by tertiles, patients with low (<4), intermediate (4-15), and high (>15) risk scores had significantly different arrhythmic event rates (2%, 10%, 16%, respectively; p<0.001). The integrated discrimination improvement (IDI) by adding MIBG imaging results to the risk model, which included SBP and LVEF, was 0.45 (absolute IDI=0.01; 95% CI, 0.0007 to 0.014), which demonstrated a 45% improvement in discriminatory ability with the addition of MIBG results.

Jain et al (2014) evaluated the incremental predictive value of adding MIBG imaging to four published heart failure risk models using data from ADMIRE-HF.(13) The four risk models varied in the patient populations from which they were derived and in their predictor variables. In the ADMIRE-HF population, the four models had modest discrimination for identifying patients at risk of experiencing the composite primary endpoint, heart failure progression necessitating hospital admission, life-threatening arrhythmia, or cardiac death (C statistic range, 0.611-0.652). When the H/M ratio was added to the risk prediction models, the IDI had an absolute improvement of 2.1% to 3.0% in each model, representing a relative improvement in predictive utility ranging from 33% to 59%.

Narula et al (2015) reported on the ADMIRE-HF extension study (ADMIRE-HFX), which extended the follow up to a median of 24 months and focused specifically on the predictive value of MIBG imaging for mortality prediction.(14) The primary end point for this extension study was all-cause mortality, which was analyzed using two coprimary analysis methods, proportional hazards and logistic regression. In both the multivariate Cox proportional hazards analysis and the multivariate logistic regression analysis with receiver operating characteristic curve comparisons, the H/M ratio was a significant additional predictor for all-cause mortality (hazard ratio [HR], 0.08; p<0.001; odds ratio, 0.07; 95% CI, 0.20 to 0.238, respectively).

Agostini et al (2021) continued to evaluate the value of MIBG imaging for predicting mortality, cardiac death, and arrhythmic events in the ADMIRE-HF study at a median follow-up of 62.7 months.(15) Results revealed that all-cause mortality (38.4% vs. 20.9%) and cardiac mortality (16.8% vs. 4.5%) were significantly increased for those patients with a H/M ratio < 1.6 versus those with a ratio ≥ 1.6 (p<.05 for both comparisons). Patients with preserved sympathetic innervation of the myocardium (H/M ≥ 1.6) also had a significantly lower risk of 5-year mortality (17.1% vs. 34.3%; p<.0001), 5-year cardiac mortality (4.6% vs. 15.8%; p<.0001), and sudden cardiac death or potentially life-threatening arrhythmias (10.9% vs. 21.1%; p=.0002). A trend toward a higher mortality for subjects with H/M < 1.6 was seen reaching significance for patients with a LVEF of 25 to ≤35% only.

Other Prospective Studies

For patients with heart failure who do not have reduced LVEF (i.e., LVEF of at least 50%), several prospective studies have found the MIBG is an independent predictor of cardiac outcomes.(16-20) For example, Nakata et al (2013) published the results of a pooled patient-level analysis of six prospective heart failure studies from Japan in which cardiac MIBG imaging was used.(21) The 6 studies initially included 1360 patients, but 38 patients were excluded (32 due to loss to follow-up, 6 due to follow-up <1 year) for the present analysis. The H/M ratio and the washout rate of MIBG activity were the primary cardiac sympathetic

innervation markers. In a multivariate Cox proportional hazards model, the late H/M ratio was significantly associated with the primary outcome of all-cause mortality ($p < 0.001$). The addition of the H/M ratio to a model of cardiac risk based on clinical information led to a net reclassification improvement of 0.175 ($p < 0.001$).

In a prospective single-center study by Doi et al (2012) evaluated the prognostic value of MIBG activity assessment in 178 heart failure patients without reduced LVEF.(17) Eligibility for the trial included symptomatic heart failure and LVEF more than 50%. Mean LVEF in the sample was 64.5%. Cardiac planar and tomographic MIBG images were obtained 15 to 30 minutes (early) and 4 hours (late) after the agent was injected. MIBG activity was quantified as the H/M ratio by an experienced technician blinded to clinical data. Patients were followed for a mean of 80 months (minimum, 3 months). The primary end points were cardiac events consisting of death, sudden cardiac death, pump failure, or rehospitalization due to the progression of heart failure. During follow-up, cardiac events were documented in 34 (19%) of 178 patients. Events included 7 deaths due to pump failure, 2 sudden deaths, and 25 readmissions due to heart failure progression. There were significantly lower early and late MIBG levels in patients who experienced cardiac events compared to those without events. This study evaluated MIBG activity as a continuous variable; it did not use a cutoff (e.g., an H/M ratio of at least 1.60), as was used to indicate decreased risk in the ADMIRE-HF study.(10) The mean (SD) early H/M ratio level was 1.86 (0.38) in the group with cardiac events and 2.00 (0.31) in the group without cardiac events. The mean (SD) late H/M ratio was 1.64 (0.35) in the group with and 1.89 (0.33) in the group without cardiac events. In a multivariate analysis, use of diuretics, late atrial diameter, and late H/M ratio were all independent predictors of cardiac events.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

As noted above, numerous prospective studies have indicated the MIBG imaging is associated as a prognostic marker with heart failure mortality. No studies were identified that evaluated the impact of cardiac sympathetic innervation assessed by MIBG on treatment decisions for heart failure or that evaluated whether managing heart failure patients with this test (vs managing patients without the test) leads to patient management decisions that improve health outcomes.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

A systematic review by Treglia et al (2013) included 33 studies, primarily performed in Europe and Japan that compared MIBG imaging results in patients with heart failure before and after receiving medication treatment.(22) Reviewers provided brief descriptions of the findings of individual studies; they did not pool study results. Studies addressed different classes of medications (e.g., β -blockers, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers) and varied in the MIBG parameters that were used. The reviewers did not report the number of studies that had statistically significant findings, but they described a number of studies that found significant associations between medication treatment and changes in one or more MIBG parameters. They also described some studies that found

significant associations between changes in one or more MIBG parameters and cardiac outcomes in patients receiving medication treatment. However, none of the studies used MIBG imaging results to guide medication treatment choices or compared management strategies that did and did not include MIBG imaging.

Management changes that might be made as a result of MIBG myocardial imaging are uncertain. It is possible that medication therapy could be intensified based on MIBG scanning that indicated poor prognosis. However, evidence is lacking that such a management change would result in improved outcomes. It is also possible that medications that block sympathetic overactivity (e.g., β -blockers or ACE inhibitors) could be adjusted to achieve an optimal H/M ratio. It is also not known whether such medication adjustments made as a result of MIBG imaging would lead to improvements in health outcomes.

Section Summary: Myocardial Sympathetic Innervation Imaging in Heart Failure

The available evidence has demonstrated that MIBG imaging is a predictor of future cardiac events and mortality in patients with heart failure. Numerous prospective studies have evaluated this question and a systematic review that pooled the highest quality studies estimated that cardiac events were approximately 2 times more frequent for patients with a lower MIBG ratio than for those with a higher ratio. The primary study on which the FDA approval was based reported that a low MIBG ratio was associated with a substantially higher mortality rate at 2 years. Data from this same study reported that the addition of the MIBG score to a known prognostic index (the SHFM) resulted in improved predictive accuracy. The evidence does not support a finding that MIBG imaging can be used to direct management in patients with heart failure. Numerous studies have correlated medication changes with changes in MIBG imaging. However, these studies do not provide evidence on the type of management changes that might follow from MIBG imaging. Further studies are needed to determine the impact of MIBG imaging on health outcomes.

Supplemental Information

PRACTICE GUIDELINES AND POSITION STATEMENTS

National Heart, Lung, and Blood Institute

The National Heart, Lung, and Blood Institute (2011) published a report on the translation of cardiovascular molecular imaging.(23) In regard to heart imaging with iodine 123 meta-iodobenzylguanidine (MIBG), the report cited the AdreView Myocardial Imaging for Risk Evaluation in Heart Failure ADMIRE-HF trial,(10) and stated that additional clinical trials would be needed to determine the efficacy of heart failure management strategies using MIBG compared with usual care without MIBG imaging.

American Heart Association et al

The American Heart Association, American College of Cardiology, and the Heart Failure Society of American published joint guidelines on the management of heart failure in 2022.(24) These guidelines did not address the use of MIBG imaging in heart failure management.

U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS

Not applicable.

ONGOING AND UNPUBLISHED CLINICAL TRIALS

A search of ClinicalTrials.gov showed no relevant clinical trials.

Regulatory Status

AdreView® (Iobenguane I 123) Injection (GE Healthcare - 2008) was approved via the Food and Drug Administration new drug application process (22-290) for the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests.(5)

The Food and Drug Administration (2013) approved a supplemental new drug application (22-290/S-001) for AdreView® and expanded the labeled indication to include scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the H/M ratio of radioactivity uptake in patients with New York Heart Association class II or class III heart failure and left ventricular ejection fraction less than 35%.(6)

Government Regulations

National:

There is no national coverage determination for myocardial sympathetic innervation imaging with ¹²³meta-iodobenzylguanidine.

Local:

There is no local coverage information for myocardial sympathetic innervation imaging with ¹²³meta-iodobenzylguanidine.

Wisconsin Physicians Service Insurance Corporation [08202] – MI, Category III Codes (L35490), Rev. Eff. 1/1/25 does not include 0331T-0332T on the list of covered procedures.

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Positron Emission Tomography (PET Scans) for Cardiac Applications
 - Myeloperoxidase (MPO) Immunoassay for Cardiac Disease Risk
-

References

1. Centers for Disease Control and Prevention (CDC). Heart Failure.2024;
https://www.cdc.gov/heart-disease/about/heart-failure.html?CDC_AAref_Val=https://www.cdc.gov/heartdisease/heart_failure.htm.
Accessed February 3, 2025.

2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. Feb 22 2022; 145(8): e153-e639. PMID 35078371
3. Chirumamilla A, Travin MI. Cardiac applications of 123I-MIBG imaging. *Semin Nucl Med* 2011; 41(5):374-87.
4. Flotats A, Carrio I, Agostini D et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. *Eur J Nucl Med Mol Imaging* 2010; 37(9):1802-12.
5. Food and Drug Administration (FDA). Approval letter: NDA 22-290. AdreView®, (Iobenguane I 123) 2mCi/mL Injection. 2008; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022290s000toc.cfm. Accessed February 3, 2025.
6. Food and Drug Administration (FDA). Supplemental Approval letter: NDA 22-290/S-001. AdreView (Iobenguane I 123) Injection. 2013; https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022290orig1s001ltr.pdf. Accessed February 3, 2025.
7. Food and Drug Administration (FDA). Highlights of Prescribing Information: AdreView (Iobenguane I 123 Injection) for Intravenous Use. 2013; http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022290s001lbl.pdf. Accessed February 3, 2025.
8. Verschure DO, Veltman CE, Manrique A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. *Eur Heart J Cardiovasc Imaging*. Sep 2014;15(9):996-1003. PMID 24686260
9. Verberne HJ, Brewster LM, Somsen GA et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. *Eur Heart J* 2008; 29(9):1147-59.
10. Jacobson AF, Senior R, Cerqueira MD et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. *J Am Coll Cardiol* 2010; 55(20):2212-21.
11. Ketchum ES, Jacobson AF, Caldwell JH et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. *J Nucl Cardiol* 2012; 19(5):1007-16.
12. Al Badarin FJ, Wimmer AP, Kennedy KF, et al. The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: incremental prognostic benefit of cardiac 123I-MIBG scintigraphy. *J Nucl Cardiol*. Aug 2014;21(4):756-762; quiz 753-755, 763-755. PMID 25015681
13. Jain KK, Hauptman PJ, Spertus JA, et al. Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models. *J Card Fail*. Aug 2014;20(8):577-583. PMID 24951931
14. Narula J, Gerson M, Thomas GS, et al. (1)(2)(3)I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study. *J Nucl Med*. Jul 2015;56(7):1011-1018. PMID 26069309
15. Agostini D, Ananthasubramaniam K, Chandna H, et al. Prognostic usefulness of planar 123 I-MIBG scintigraphic images of myocardial sympathetic innervation in congestive heart failure: Follow-Up data from ADMIRE-HF. *J Nucl Cardiol*. Aug 2021; 28(4): 1490-1503. PMID 31468379

16. Akutsu Y, Kaneko K, Kodama Y, et al. Iodine-123 mIBG Imaging for predicting the development of atrial fibrillation. JACC Cardiovasc Imaging. Jan 2011;4(1):78-86. PMID 21232708
17. Doi T, Nakata T, Hashimoto A, et al. Synergistic prognostic values of cardiac sympathetic innervation with left ventricular hypertrophy and left atrial size in heart failure patients without reduced left ventricular ejection fraction: a cohort study. BMJ Open. 2012;2(6). PMID 23204136
18. Katoh S, Shishido T, Kutsuzawa D et al. Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction. Ann Nucl Med 2010; 24(9):679-86.
19. Minamisawa M, Izawa A, Motoki H, et al. Prognostic Significance of Neuroadrenergic Dysfunction for Cardiovascular Events in Patients with Acute Myocardial Infarction. Circ J. 2015;79(10):2238-2245. PMID 26155851
20. Scala O, Paolillo S, Formisano R, et al. Sleep-disordered breathing, impaired cardiac adrenergic innervation and prognosis in heart failure. Heart. Jun 23, 2016. PMID 27340199
21. Nakata T, Nakajima K, Yamashina S et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013; 6(7):772-84.
22. Treglia G, Stefanelli A, Bruno I et al. Clinical usefulness of myocardial innervation imaging using Iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: an overview. Eur Rev Med Pharmacol Sci 2013; 17(1):56-68.
23. Buxton DB, Antman M, Danthi N et al. Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging. Circulation 2011; 123(19):2157-63.
24. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. May 03 2022; 79(17): e263-e421. PMID 35379503
25. Wisconsin Physicians Service Insurance Corporation [08202] – MI, MAC Part B (J8), Category III Codes (L35490), Rev. Eff. 6/11/22.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 3/11/26, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
9/1/13	6/18/13	6/26/13	Joint policy established
1/1/15	10/24/14	11/3/14	Routine maintenance; adopted BCBSA version of policy; no change in policy position.
1/1/16	10/13/15	10/27/15	Routine maintenance
1/1/17	10/11/16	10/11/16	Routine maintenance
1/1/18	10/19/17	10/19/17	Routine maintenance
1/1/19	10/16/18	10/16/18	Routine maintenance
7/1/19	4/16/19		Routine maintenance
7/1/20	4/14/20		Routine maintenance
7/1/21	4/20/21		Routine maintenance
7/1/22	4/19/22		Routine maintenance
7/1/23	4/18/23		Routine maintenance (slp) Vendor Managed: N/A
7/1/24	4/16/24		Routine maintenance (slp) Vendor managed: N/A
7/1/25	4/15/25		• Routine maintenance (slp) • Vendor managed: N/A • Heart Failure added to title for clarification
7/1/26	4/21/26		• Routine maintenance (slp/lk) • Vendor managed: N/A • Policy reformatted

Next Review Date: 2nd Qtr, 2027

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: MYOCARDIAL SYMPATHETIC INNERVATION IMAGING

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not covered
BCNA (Medicare Advantage)	Refer to the Medicare information under the Government Regulations section of this policy.
BCN65 (Medicare Complementary)	Coinurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.